Janux Therapeutics, Inc.JANXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -82.56% | -100.00% | -100.00% | -100.00% | +2177.90% |
| Gross Profit Growth | -78.24% | -100.00% | -100.00% | -100.00% | +2063.78% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +19.51% | +21.74% | +25.98% | +13.68% | +13.54% |
| Weighted Average Shares Diluted Growth | +19.51% | +21.74% | +25.98% | +13.68% | +13.54% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +26.79% | -52.80% | +41.78% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +79.66% | +179.05% | +52.51% | +49.29% | +47.44% |
| Book Value per Share Growth | +57.32% | +143.98% | +22.56% | +32.48% | +31.10% |
| Debt Growth | -5.87% | -6.18% | -6.50% | -6.84% | -3.29% |
| R&D Expense Growth | +56.53% | +69.97% | +78.07% | +132.68% | +86.04% |
| SG&A Expenses Growth | +174.42% | +29.24% | +44.50% | +42.91% | -42.71% |